Trials / Completed
CompletedNCT02202226
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AF35700 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-02-01
- First posted
- 2014-07-28
- Last updated
- 2015-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02202226. Inclusion in this directory is not an endorsement.